(Date:8/29/2008)...nancial implications of SSDI benefits, online fina...h disabilities. , Bellevi...to move forward after a diagnosis of a long-term d... that individuals do as much as they can to unders.../www.allsup.com/ [Allsup], which represents peopl...
(Date:8/28/2008)... - Nine new Centers opened to date in 2008 VAN...al Corporation,(CRM:TSX-V) announced today unaudit... 30, 2008 (all figures are in US dollars). Revenue...d 138% to $1,653,891 compared to,$695,994 for the ...ded June,30, 2008 increased 150% to $3,001,333 com...
(Date:8/28/2008)...ecially for the impaired, study says , ,... says that 13 percent of American seniors suffer m... University of Chicago researchers said the chief ...dvantage of financially (3.5 percent), and physica...niors with physical impairments were most likely t...
(Date:8/28/2008)... Guava Technologies, Inc.,announced the commenceme...ovide drug discovery researchers with an automated...e agreement is a key component of a larger,strateg...e is a direct,response to a voiced need for sophis... throughput research in a compact, automated, and ...
Breaking Medicine News(10 mins):Health News:Social Security Disability Can Be Key to Financial Future 2Health News:Social Security Disability Can Be Key to Financial Future 3Health News:Social Security Disability Can Be Key to Financial Future 4Health News:Social Security Disability Can Be Key to Financial Future 5Health News:Social Security Disability Can Be Key to Financial Future 6Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:13% of Seniors Report Being Mistreated 2Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 2Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 3(Date:8/27/2008)..., from BLISS-52 trial, expected by mid-2009 - - D...by fall 2009 -, ROCKVILLE, Md., Aug. 27 /PRNewswi...aq: HGSI ) today announced it has completed enrol...f two pivotal Phase 3,randomized clinical trials o...ive systemic lupus erythematosus (SLE). Belimumab ...
(Date:8/26/2008)...ents can drive safely six weeks following surgical...SNewswire/ -- Six weeks following,bunion surgery, ...e able to,get back behind the wheel of a car again...e Journal of Bone and Joint Surgery ( http://www.j...sponse in patients who underwent a,first metatarsa...
(Date:8/26/2008)...ewswire/ -- Omeros Corporation today announced the... trial investigating,OMS103HP in arthroscopic ante...y. OMS103HP is an investigational drug product tha... is designed to improve postoperative,knee functio...patients an,earlier return to work. The article ti...
(Date:8/25/2008)...g. 25 /- Anthera Pharmaceuticals,Inc....oping,anti-inflammatory drugs, today announced the...coronary events with Near-term Cardiovascular,Infl...xamine the impact of,varespladib when administered...Syndrome (ACS) event., The FRANCIS trial is desig...
Breaking Medicine Technology:Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Braking After Bunion Surgery 2Braking After Bunion Surgery 3Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 3Shaking may cause brain damage and serious long term effects to infants 1376 1Shaking may cause brain damage and serious long term effects to infants 1376 2American College of Physicians publishes The Fenway Guide to LGBT Health 1374 1American College of Physicians publishes The Fenway Guide to LGBT Health 1374 2IMPACT initiative looks to improve patient participation in clinical trials 1372 1IMPACT initiative looks to improve patient participation in clinical trials 1372 2New genetic research into nicotine addiction shows promise for personalized treatment 421 1New genetic research into nicotine addiction shows promise for personalized treatment 421 2...esented at ASCO with cediranib - a selective,VEGF ...ents alive,and progression- free at six months(1),...he,investigational agent cediranib (AZD2171) were ...can Society of Clinical Oncology,(ASCO) from a stu...an invasive form of brain tumor with a high unmet ...
...atients With Follicular Lymphoma Reported,Today at.../PRNewswire/ -- GlaxoSmithKline plc,announced toda... a,single one-week course of frontline treatment w... and Iodine I-131 Tositumomab) in,76 patients with...,lymphoma (NHL). This regimen was found to induce ...
Other Medicine Technology:Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 2Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 3Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens.
The Directigen Meningitis Individual Tests are presumptive latex slide agglutination tests for the direct qualitative detection of antigens to H. influenzae type b, S. pneumoniae, N. meningitid
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease).
The AP250 Auto Projector is a remote-controlled, programmable, random-access, high-resolution, ophthalmic projector.
Medicine Products: